In a recent study, researchers found that an inhaled form of a high blood pressure medication has the potential to treat certain types of anxiety as well as pain.
The study was conducted by the Centre for Addiction and Mental Health (CAMH).
Anxiety disorders are usually treated with different types of medications, such as antidepressants, and psychotherapy.
Amiloride offers a new approach, as a short-acting nasal spray that could be used to prevent an anxiety attack.
The medication has been used as an oral treatment for decades for hypertension, and as an inhaled spray in a few experimental studies of cystic fibrosis.
It is inhaled so that it could immediately access the brain.
The study showed that inhaled amiloride may prove to have benefits for panic disorder, which is typically characterized by spells of shortness of breath and fear when people feel anxiety levels rising.
The study was based on understanding the key physiological changes in brain functioning that are linked to anxiety and pain sensitivity.
The researchers then tested a molecule, amiloride, which targets this functioning.
The results showed that it reduced the physical respiratory signs of anxiety and pain in a preclinical model of illness.
This therapeutic effect didn’t occur when amiloride was administered in the body, as it didn’t cross the blood-brain barrier and did not reach the brain.
The study is based on years of research into how a person’s early life experiences affect their genes.
Childhood adversity, such as loss or separation from parents, increases the risk of anxiety disorders and pain, among other health issues.
At a molecular level, these negative life experiences are linked to changes in some genes of the ASIC (acid-sensing-ion-channels) family.
While the DNA itself doesn’t change, the way it functions is affected.
DNA is converted into working proteins through a process called gene expression. As a result of childhood adversity, some ASIC genes showed increased expression and epigenomic changes.
“Epigenomic” refers to changes in gene regulation that can be inherited by children.
Overlapping genetic changes were also seen in blood taken from twins who responded to specific tests designed to provoke panic.
These genetic changes are linked to physical symptoms. Breathing can be affected, due to over-sensitivity to higher carbon dioxide levels in the air.
In such situations, a person might hyperventilate and experience growing anxiety. Preclinical and human data are strikingly similar in this regard.
The team suggests that as a treatment, amiloride turned out to be very effective preclinically.
The next step of the research is to test whether it eases anxiety symptoms.
The team is now launching a pilot clinical trial, supported through a seed grant from CAMH’s new Discovery Fund. Collaborators at the University of Utah are testing the drug’s safety.
The researchers are therefore further ahead than if they had to develop and test an entirely new medication.
The lead author is Dr. Marco Battaglia at CAMH.
The study is published in the Journal of Psychopharmacology.
Copyright © 2018 Knowridge Science Report. All rights reserved.
Source: Journal of Psychopharmacology.
